Ulcerative Colitis

Upadacitinib was not approved by the FDA until 2022 for patients with ulcerative colitis.

The 12-24 session counseling program also resulted in improvements in sleep quality, fatigue level, and stress levels for patients with inflammatory bowel disease.

The majority of patients who achieved persistence at the 12 month mark were also corticosteroid free.

The product is a combination of herbal compounds curcumin and QingDai called CurQD.

Microscopic inflammation can be an important indicator of disease activity in patients with ulcerative colitis.

There was no differences in serious adverse event rates between patients treated with the combination therapy and patients who withdrew from infliximab or immunosuppressant therapy.

The guidelines include advocating for more preventative care and changing how the disease is diagnosed.

Gut microbiota diversity was lower in below average responders, while 39.5% of participants had a serological response below the geometric mean.

Ulcerative colitis was considered an independent risk factor, while Crohn’s disease and unclassified inflammatory bowel disease were not.

The results show patients with preclinical IBD had an increased in primary care visits up to 3-5 years prior to a diagnosis.

In 2021, the USPSTF changed guidance on colorectal cancer screenings, reducing the recommended age of a colonoscopy from 50 to 45 years.

There was also higher neutralizing antibody titers against BA.4/5 with a lower hazard risk in the group with a breakthrough infection.

Prometheus Biosciences is expected to begin phase 3 trials for the treatment in 2023.

The male gender was positively associated with a higher risk of serious infection at month 12 and penetrating disease behavior was positively associated with 12-month treatment persistence.

David P. Hudesman, MD, discusses clinical implications from ACG 2022 data on ustekinumab therapy for the management of ulcerative colitis and shares advice for managing patients with the disease.

David P. Hudesman, MD, reviews long-term extension study data for the corticosteroid-sparing effects of ustekinumab on ulcerative colitis as presented at ACG 2022.

The treatment is a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, can possibly reduce abdominal adhesions and accelerate the return of bowel function following gastrointestinal surgery.

Only recent hospitalization and proton pump inhibitor use was deemed an independent risk factor for C difficile infections.

David P. Hudesman, MD, reviews data presented at the ACG 2022 Annual Scientific Meeting on the safety and efficacy of ustekinumab for ulcerative colitis treatment.

David P. Hudesman, MD, provides insight on approaching induction therapy and maintenance therapy for patients with relapsing ulcerative colitis.

In the QUSAR study, 80% of patients treated with guselkumab achieved a clinical response.

For safety, 24.1% of the entire study population experienced adverse events, with 18 participants developing tuberculosis.

The investigators found that depression increased the odds of systemic steroid administrations, the use of 2 or more molecular targeted drugs, and surgery in patients with ulcerative colitis.

New pooled phase 3 data presented at ACAAI 2022 supports the FDA's approval of dupilumab for eosinophilic esophagitis.

More than 70% of patients treated with RBX2660 were recurrence free at the 8 week mark.

The approval of risankizumab represents the first ever IL-23 approved by the FDA for IBD.

Patients with obesity have higher costs and longer hospital stays for IBD.

Up to 2% of patients with IBD also have EoE.

Guselkumab bested placebo in clinical results of patients with ulcerative colitis.

In a late-breaking abstract, the investigators compared antibody levels at month 6 compared to month 1.